Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Adanate, Inc
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically documented, incurable or metastatic solid tumor that is advanced (nonresectable) or recurrent and progressing since the last antitumor therapy and for which no recognized standard therapy exists
Eastern Cooperative Oncology Group (ECOG) performance status ≤2
Measurable disease per RECIST v1.1 or per other criteria best suited for the specific tumor type being evaluated
Adequate organ function
You may not be if
Treatment with any local or systemic antineoplastic therapy (including chemotherapy, hormonal therapy, or radiation) within 2 weeks prior to the first dose of ADA-011
Chronic use of corticosteroids in excess of 10 mg daily of prednisone or equivalent within 4 weeks prior to the first dose of ADA-011
Major trauma or major surgery within 4 weeks prior to the first dose of ADA-011
AEs from prior anticancer therapy that have not resolved to Grade ≤1 except for alopecia
Known, central nervous system (CNS) disease involvement, or prior history of NCI CTCAE Grade ≥3 drug-related CNS toxicity.
Evidence of active uncontrolled viral, bacterial, or systemic fungal infection
Active SARS-CoV-2 infection, irrespective of symptoms.
History or risk of severe, chronic, untreated, or currently active autoimmune disease
Prior solid organ transplant or has had an allogenic hematopoietic stem cell transplant within the past 20 years
Pregnant, lactating, or breastfeeding
Clareo Health | A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors
